Quanta Announces IND Clearance by U.S. FDA for QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates
Additionally, the Phase 1 clinical trial evaluating QTX3034, an oral G12D-preferring multi-KRAS inhibitor, as a monotherapy and in combination with cetuximab, continues to enroll patients, and data is ...
Pharmabiz1d
Quanta receives US FDA clearance to begin phase 1 trial of QTX3544, an oral G12V-preferring, dual ON/OFF state, multi-KRAS inhibitor
Quanta receives US FDA clearance to begin phase 1 trial of QTX3544, an oral G12V-preferring, dual ON/OFF state, multi-KRAS inhibitor: Radnor, Pennsylvania Friday, January 10, 2025 ...
Pharmaceutical Technology5d
QTX-3046 by Quanta Therapeutics for Colorectal Cancer: Likelihood of Approval
QTX-3046 is under clinical development by Quanta Therapeutics and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 7 ...
Yahoo Finance19d
Quantum eMotion Deploys its Quantum-Safe Security Platform for Digital Therapeutics in Landmark Commercial Alliance
As the digital therapeutics field continues to revolutionize ... QeM has become a pioneering force in classical and quantum cybersecurity solutions thanks to its patented Quantum Random Number ...
Pharmaceutical Technology5d
QTX-3046 by Quanta Therapeutics for Lung Cancer: Likelihood of Approval
QTX-3046 is under development for the treatment of solid tumor, colorectal, pancreatic, endometrial cancer and lung cancer. It is administered through oral route. The drug candidate acts by targeting ...